Group by:
Item Type |
DateNumber of items: 5.
Journal article
Krupka, C.; Lindl, B.; Kischel, R.; Kufer, P.; Lichtenegger, F. S.; Köhnke, T.; Augsberger, C.; Altmann, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, Marion
(2017):
Influence of Cytoreductive and Immunmodulatory Drugs on Bispecific T-Cell Engager-Based Approaches in AML.
In: Annals of Hematology, Vol. 96: S81-S82
Krugmann, J.; Sterlacci, W.; Veits, L.; Vieth, M.; Rieker, R. J.; Altmann, T.; Sokolowski, T. und Fend, F.
(2016):
Aberrant CD68 expression is a rare pitfall in the diagnosis of primary amelanotic malignant melanoma in ascites fluid.
In: Cytopathology, Vol. 27, No. 4: pp. 295-296
Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Köhnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmüller, G. und Subklewe, M.
(2016):
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
In: Leukemia, Vol. 30, No. 2: pp. 484-491
Krupka, C.; Lindl, B.; Platzer, J.; Brauneck, F.; Kischel, R.; Kufer, P.; Lichtenegger, F. S.; Köhnke, T.; Rothe, M.; Deiser, K.; Augsberger, C.; Altmann, T.; Spiekermann, K.; Hiddemann, W. und Subklewe, M.
(2016):
Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML.
In: Oncology Research and Treatment, Vol. 39: pp. 84-85
Lichtenegger, F. S.; Deiser, K.; Rothe, M.; Krupka, C.; Schnorfeil, F. M.; Augsberger, C.; Köhnke, T.; Bücklein, V; Altmann, T.; Moosmann, A.; Brüggemann, M.; Heemskerk, M. H. M.; Wagner, B.; Hiddemann, W.; Bigalke, I; Kvalheim, G. und Subklewe, M.
(2016):
Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade.
In: Oncology Research and Treatment, Vol. 39: p. 135
This list was generated on Sun Oct 6 05:42:56 2024 CEST.